T2 Biosystms Valuation
| TTOODelisted Stock | USD 0.18 0.05 21.74% |
T2 Biosystms seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of T2 Biosystms from examining the entity fundamentals such as shares owned by institutions of 73.51 %, and Return On Asset of -0.9 as well as evaluating its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that T2 Biosystms' price fluctuation is out of control at this time. Calculation of the real value of T2 Biosystms is based on 3 months time horizon. Increasing T2 Biosystms' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since T2 Biosystms is currently traded on the exchange, buyers and sellers on that exchange determine the market value of TTOO Pink Sheet. However, T2 Biosystms' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.18 | Real 0.17 | Hype 0.18 | Naive 0.25 |
The intrinsic value of T2 Biosystms' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence T2 Biosystms' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of T2 Biosystms helps investors to forecast how TTOO pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of T2 Biosystms more accurately as focusing exclusively on T2 Biosystms' fundamentals will not take into account other important factors: T2 Biosystms Total Value Analysis
T2 Biosystms is at this time estimated to have valuation of 21.91 M with market capitalization of 10.48 M, debt of 49.5 M, and cash on hands of 13.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the T2 Biosystms fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
21.91 M | 10.48 M | 49.5 M | 13.21 M |
T2 Biosystms Investor Information
About 74.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.03. T2 Biosystms had not issued any dividends in recent years. The entity had 1:100 split on the 13th of October 2023. Based on the key indicators related to T2 Biosystms' liquidity, profitability, solvency, and operating efficiency, T2 Biosystms is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.T2 Biosystms Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. T2 Biosystms has an asset utilization ratio of 20.67 percent. This suggests that the Company is making $0.21 for each dollar of assets. An increasing asset utilization means that T2 Biosystms is more efficient with each dollar of assets it utilizes for everyday operations.T2 Biosystms Ownership Allocation
T2 Biosystms secures a total of 21.04 Million outstanding shares. The majority of T2 Biosystms outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to take positions in T2 Biosystms to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in T2 Biosystms. Please pay attention to any change in the institutional holdings of T2 Biosystms as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.T2 Biosystms Profitability Analysis
The company reported the previous year's revenue of 7.19 M. Net Loss for the year was (50.08 M) with loss before overhead, payroll, taxes, and interest of (24.77 M).About T2 Biosystms Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of T2 Biosystms. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of T2 Biosystms based exclusively on its fundamental and basic technical indicators. By analyzing T2 Biosystms's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of T2 Biosystms's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of T2 Biosystms. We calculate exposure to T2 Biosystms's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of T2 Biosystms's related companies.T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. T2 Biosystems operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 182 people.
8 Steps to conduct T2 Biosystms' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates T2 Biosystms' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct T2 Biosystms' valuation analysis, follow these 8 steps:- Gather financial information: Obtain T2 Biosystms' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine T2 Biosystms' revenue streams: Identify T2 Biosystms' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research T2 Biosystms' industry and market trends, including the size of the market, growth rate, and competition.
- Establish T2 Biosystms' growth potential: Evaluate T2 Biosystms' management, business model, and growth potential.
- Determine T2 Biosystms' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate T2 Biosystms' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
T2 Biosystms Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2.6 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in TTOO Pink Sheet
If you are still planning to invest in T2 Biosystms check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the T2 Biosystms' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |